Annals of Oncology 25 (Supplement 4): iv255–iv279, 2014 doi:10.1093/annonc/mdu336.40
genitourinary tumours, prostate 792P
TREATMENT PATTERNS IN PATIENTS (PTS) WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PREVIOUSLY TREATED WITH DOCETAXEL (DOC)-BASED CHEMOTHERAPY (CTX): PROXIMA
H. Akaza1, G. Procopio2, C. Pripatnanont3, G. Facchini4, S. Fava5, D. Wheatley6, K.C. Leung7, M. Butt8, A. Silva9, L. Castillo10, G. Fountzilas11, S. Hitier12, E.B. Ecstein-Fraisse13, S. Bensfia14, M. Özgüroğ lu15 1 Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, JAPAN 2 Oncologia Medica, Istituto Nazionale Tumori, Milan, ITALY 3 Department of Surgery, Prince of Songkla University, Songkla, THAILAND 4 Medical Oncology, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, ITALY 5 Oncology, Ospedale di Legnano, Milan, ITALY 6 Oncology, Royal Cornwall Hospital, Truro, UK 7 Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, CHINA 8 Queen’s Centre for Oncology, Castle Hill Hospital, Hull, UK 9 Oncology, Instituto de Cancer do Ceará, Fortaleza, BRAZIL 10 Medical Oncology, Hospital Oncológico Miguel Pérez Carreño, Valencia, VENEZUELA 11 Medical Oncology Clinic, Papageorgiou Hospital, Aristotle University of Thessaloniki, Thessaloniki, GREECE 12 Statistics, Sanofi, Chilly-Mazarin, FRANCE 13 Medical Operations, Sanofi K.K., Tokyo, JAPAN 14 Research and Development, Sanofi, Cambridge, MA, USA 15 Department of Medical Oncology, Istanbul University Cerrahpasa Faculty of Medicine, Istanbul, TURKEY
Aim: PROXIMA is a prospective, international registry study of treatment patterns over 12 months and survival at 24 months in pts with mCRPC during or after DOC failure. Interim regional management and baseline data are presented. Methods: Men aged ≥18 yrs with mCRPC who progressed during or after a DOC-based regimen were included. Results: 906 pts (Asia 19.5%; Europe [Eur] 49.0%; Latin America [LatAm] 14.2%; other 17.2%) from 167 randomly selected sites were included. The most frequent hospital type was public in Eur (80.3%), private in LatAm (80.6%), and teaching/ university in Asia (55.6%) and other countries (74.4%). The most frequent specialty was medical oncologist in Eur (90.2%) and LatAm (100%), urologist in Asia (80.6%) and radiation oncologist in other countries (48.7%). A multidisciplinary approach was predominant in all regions. Median age was 71.0 yrs (range 42–91) and median time from diagnosis to inclusion was 55.0 months (2.0–361.3). At diagnosis, median Gleason score was 8.0 and median PSA was 63.5 ng/ml. At study entry, metastatic sites were bone (90.6%), lymph node (30.5%) and visceral/soft tissue (19.5%). Pts received 1 (85.3%), 2 (12.1%) or ≥3 (2.7%) lines of DOC therapy before entry, with a similar pattern across regions. Median cumulative DOC dose was 540 mg/m2 and was similar across regions. 207 pts (22.8%) received further therapy after DOC and before inclusion, more frequently in Eur (29.5%) vs other regions (range 11.3–20.9%) (Table). Post-DOC, use of CTX (12.4%) vs hormonal therapy (11.5%) was similar, and of pts receiving CTX, taxane therapy (non-DOC) was more common in Eur (6.8%) vs elsewhere (range 0.6–3.1%). 699 pts were yet to be treated post-DOC, but will be followed to evaluate treatment patterns. Conclusions: Treatment practices for mCRPC differ between global regions. Treatment following DOC failure and effect on outcome are being evaluated. Disclosure: H. Akaza: has acted as a consultant/advisor for Takeda Pharmaceutical Company Ltd, Janssen Pharmaceutical K.K. and Astellas Pharma Inc.; G. Procopio: is a member of advisory boards for Bayer, Bristol, GSK, Novartis and Pfizer and has acted as a consultant for Astellas and Janssen; S. Hitier: is an employee of Sanofi and holds Sanofi stock; E.B. Ecstein-Fraisse: is an employee of Sanofi and holds Sanofi stock; S. Bensfia: is an employee of Sanofi and holds Sanofi stock and has had involvement in corporate-sponsored research; M. Özgüroğlu: participated in advisory boards for Sanofi. All other authors have declared no conflicts of interest.
Patients, N (%)
Asia n = 177
Europe n = 444
Latin America n = 129
Other n = 156
Total N = 906
Post-docetaxel treatment at baseline Chemotherapy Taxane Hormonal agent
20 (11.3) 12 (6.8) 1 (0.6) 11 (6.2)
131 (29.5) 70 (15.8) 30 (6.8) 65 (14.6)
27 (20.9) 16 (12.4) 4 (3.1) 10 (7.8)
29 (18.6) 14 (9.0) 4 (2.6) 18 (11.5)
207 (22.8) 112 (12.4) 39 (4.3) 104 (11.5)
© European Society for Medical Oncology 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email:
[email protected].
abstracts
Table: 792P
